In this article, we describe an image analysis strategy with improved power for tracking longitudinal amyloid-β (Aβ) PET changes and evaluating Aβ-modifying treatments. Methods: Our aims were to compare the power of template-based cerebellar, pontine, and cerebral white matter reference regions to track 24-mo florbetapir standardized uptake value (SUV) ratio (SUVR) changes; to relate those changes to 24-mo clinical declines; and to evaluate Aβ-modifying treatments in Aβ-positive (Aβ1) and Aβ-negative (Aβ−) patients with probable Alzheimer dementia (pAD), in patients with mild cognitive impairment (MCI), in cognitively normal controls (NCs), and in cognitively normal apolipoprotein E4 (APOE4) carriers and noncarriers. We used baseline and follow-up (∼24 mo) florbetapir PET scans from 332 Aβ1 and Aβ− subjects participating in the multicenter Alzheimer's Disease Neuroimaging Initiative. Each of the proposed analyses included 31 pAD patients, 187 MCI patients, and 114 NCs. Cerebral-to-white matter, cerebellar, and pontine SUVRs were characterized in terms of their longitudinal variability; their power to track longitudinal fibrillar Aβ increases in Aβ1 and Aβ− subgroups and cognitively normal APOE4 carriers and noncarriers; the sample sizes needed to detect attenuated accumulation of or clearance of fibrillar Aβ accumulation in randomized clinical trials; and their ability to relate 24-mo fibrillar Aβ increases to clinical declines. Results: As predicted, cerebral-to-white matter SUVR changes were significantly less variable and had significantly greater power to detect 24-mo fibrillar Aβ increases and evaluate Aβ-modifying treatment effects in Aβ1 pAD, MCI, and NC subjects and cognitively normal APOE4 carriers. They were also distinguished by the ability to detect significant associations between 24-mo Aβ increases and clinical declines. Conclusion: A cerebral white matter reference region may improve the power to track longitudinal fibrillar Aβ increases, to characterize their relationship to longitudinal clinical declines, and to evaluate Aβ-modifying treatments in randomized clinical trials. PET ligands (1-15) have made it possible to investigate the fibrillar amyloid-b (Ab) burden in living people; to clarify its relationship to the dementia, mild cognitive impairment (MCI), and preclinical stages of Alzheimer disease (AD); to characterize the extent to which cross-sectional measurements predict subsequent clinical declines; to track longitudinal changes; and to help evaluate Ab-modifying treatments.
PET ligands (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) have made it possible to investigate the fibrillar amyloid-b (Ab) burden in living people; to clarify its relationship to the dementia, mild cognitive impairment (MCI), and preclinical stages of Alzheimer disease (AD); to characterize the extent to which cross-sectional measurements predict subsequent clinical declines; to track longitudinal changes; and to help evaluate Ab-modifying treatments.
Researchers commonly compute a semiquantitative cerebral-toreference region standardized uptake value ratio (SUVR) using PET counts from a cerebral region of interest (ROI) and from a whole cerebellar (2, 3) , cerebellar gray matter (10) , or pontine (8) reference ROI that is thought to be relatively devoid of fibrillar Ab. Less commonly, researchers compute a cerebral-to-reference region distribution volume ratio or other quantitative measures using longer, dynamically acquired PET scans and the same cerebral and reference ROIs. With conventional reference ROIs, several radioligands have demonstrated a close association between cross-sectional PET SUVR or distribution volume ratio measurements and subsequent postmortem histopathologic measurements of fibrillar Ab burden and have been used to define relevant thresholds for distinguishing between individuals with and individuals without moderate to severe neuritic plaques (2, 8, 16, 17) .
Although longitudinal analyses have the potential to track the progression of fibrillar Ab deposition over time, to relate this progression to progressive clinical decline, and to evaluate putative Ab-modifying treatments in therapeutic trials, we and others (18) (19) (20) (21) (22) have noted substantial variability in longitudinal florbetapir PET measurements of changes in fibrillar Ab deposition. Some of this variability appears to exceed that expected on the basis of biologic grounds alone (e.g., SUVR changes of .50%, in either direction, over a matter of weeks).
Among other possible causes, we wondered whether some of the variability in longitudinal Ab PET measurements might be due to between-session differences in the level or angle of a person's head in the PET scanner and its differential effects on measurements from the cerebral and more inferior cerebellar or pontine ROIs. For instance, if a person's head is positioned a shorter distance into the scanner, then the cerebellum and pons are closer to the inferior limit of the field of view. The resulting reference ROI measurements could be noisier because the 3-dimensional reconstruction algorithm would depend on fewer coincidence events; they could also be preferentially affected by scattered radiation from the body or differentially affected by the way in which the data are reconstructed and corrected for attenuation and scatter. Thus, the use of cerebral and reference ROIs located approximately the same in the axial field of view to generate SUVRs could result in reduced variability in longitudinal SUVRs and improve the power to evaluate Ab-modifying treatments in therapeutic trials. Although we have not yet attempted to clarify whether between-scan differences in scanner head positioning account for the variability in longitudinal florbetapir SUVRs, we were motivated to examine whether a cerebral white matter ROI could reduce the variability in longitudinal florbetapir SUVRs.
In this article, we describe the use of a cerebral white matter reference ROI to reduce the variability in longitudinal florbetapir SUVRs, to improve the sensitivity for detecting corresponding increases, and to improve the power for evaluating Ab-modifying treatments-an approach that is also being evaluated by other groups (18) (19) (20) (21) (22) . Although cross-sectional cerebral-to-cerebral white matter SUVRs could be affected by the combined effects of fibrillar Ab and partial-volume averaging, we surmised that this confound could be at least partly reduced in the assessment of longitudinal data because between-session differences in white matter measurements (including those related to the combined effects of small gray matter Ab PET changes and partialvolume averaging) would be relatively small.
In this study, baseline and 24-mo florbetapir PET data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were used to determine the extent to which the use of a cerebral white matter reference ROI could reduce longitudinal SUVR variability and improve the power to detect longitudinal increases in fibrillar Ab; to relate longitudinal Ab deposition and clinical progression; and to estimate the sample sizes needed for the evaluation of fibrillar Ab-modifying treatments in clinical trials. (In the accompanying report, Landau et al. used baseline cerebrospinal fluid Ab 1-42 levels and longitudinal florbetapir PET data from the ADNI to demonstrate that a cerebral white matter reference ROI was more accurate than a cerebellar ROI in terms of its accuracy in distinguishing subjects who were expected to have longitudinal SUVR increases from those who were expected to have SUVRs that remained stable over time (22) . Their data support the use of a white matter reference ROI in the analysis of longitudinal florbetapir PET scans.)
MATERIALS AND METHODS
The ADNI is a longitudinal multicenter study that provides a centralized resource for longitudinal clinical, brain imaging, and fluid biomarker data from patients with probable Alzheimer dementia (pAD), patients with MCI, and cognitively normal controls (NCs). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations. The ADNI was followed by the ADNI-GO and the ADNI-2. We referred to them collectively as ADNI in this study.
This ADNI study was approved by the institutional review boards of the participating institutions. Signed informed written consent was obtained from all participants. To date, over 1,500 adults, 55 to 90 years old, have participated in the ADNI. Current information can be found at http://www.adni-info.org/. For this study, the most fully processed PET data were downloaded from the repository for 332 participants (31 with pAD, 187 with MCI, and 114 NCs) who had undergone florbetapir PET scans at the baseline and at follow-up (;24 mo) (between May 2010 and December 2013). For our analyses, each subject group was further stratified into Ab-positive (Ab1) and Ab-negative (Ab2) subgroups. Twenty-five pAD patients, 73 MCI patients, and 26 NCs were determined to be Ab1 at the time of the baseline scan with a cerebral-to-whole cerebellar florbetapir SUVR and a threshold of 1.18, which was originally found to distinguish between people with and people without subsequent postmortem evidence of moderate to frequent neuritic plaques. Six pAD patients, 114 MCI patients, and 88 NCs were determined to be Ab2 (2,3). The NCs were also stratified into apolipoprotein E4 (APOE4) carrier (n 5 30) and noncarrier (n 5 84) subgroups irrespective of their Ab status.
The Statistical Parametric Mapping software platform (SPM8; http:// www.fil.ion.ucl.ac.uk/spm/), the FreeSurfer package (https://surfer.nmr. mgh.harvard.edu/), in-house MATLAB (The MathWorks, Inc.) scripts, and step-by-step quality control procedures were used to align each person's 24-mo PET scan with his or her baseline scan; to deform the images into the coordinates of the Montreal Neurologic Institute template; to use the template-based ROIs (independent of each person's own MR imaging) to characterize cerebral target ROI and cerebellar, pontine, and cerebral white matter reference ROI measurements from each scan; and to compute cerebral-to-respective reference region SUVRs.
Cerebral, cerebellar, and pontine ROIs were computed as previously described (2, 3) . The cerebral white matter ROI was a collection of voxels in the corpus callosum and centrum semiovale, other than those closest to gray matter or to ventricles. The template-based corpus callosum mask was from the WFU_PickAtlas toolbox (http://fmri.wfubmc. edu/software/PickAtlas). The template-based centrum semiovale mask was characterized in our laboratory with FreeSurfer to generate individual MR imaging-based ROIs in 40 randomly selected NCs, to deform the ROIs into Montreal Neurologic Institute coordinates and average them, and to include voxels with a value of at least 0.5. The templatebased cerebral, cerebellar, pontine, and cerebral white matter ROIs are shown in Figure 1 .
For each Ab1, Ab2, cognitively normal APOE4 carrier, and cognitively normal APOE4 noncarrier group, we characterized 24-mo declines in 3 commonly used clinical ratings: decreases in scores on the Mini-Mental State Examination (MMSE), increases in ratings on the 13-item version of the AD Assessment Scale Cognitive Subscale (ADAS-Cog13), and increases in scores on the Clinical Diagnostic Rating Sum of the Box (CDR-SB). We examined the within-group 24-mo cerebral-to-cerebellar, pontine, and cerebral white matter SUVR increases and such increase differences between respective Ab1 versus Ab2 or cognitively normal APOE4 carrier versus noncarrier groups. We characterized relationships between 24-mo SUVR increases and clinical declines using simple Pearson correlation coefficients. P values were computed without correction for multiple comparisons.
For each group, we also estimated the number of participants needed per arm to detect a 25% effect of treatment in a 12-mo placebo-controlled randomized clinical trial with 80% power and a 2-tailed P of 0.05, on the basis of the assumption that SUVR increases were linear. We first estimated the sample sizes needed to detect a 25% attenuation in further SUVR increases (assuming that the treatments could not remove existing Ab, an assumption that might make sense for the evaluation of a b-secretase inhibitor). We also estimated the much smaller number of participants needed per arm to detect a 25% clearance from the baseline level in the treatment group in comparison with the placebo group (an assumption that might make sense for Ab immunotherapies).
RESULTS
Demographic characteristics, clinical ratings, and follow-up durations are shown for the Ab1 and Ab2 subgroups in Table 1 and for the cognitively normal APOE4 carrier and noncarrier subgroups in Table 2 .
As shown in Table 3 , when the cerebral white matter reference ROI was used, there were small but significant SUVR increases (P , 0.005) in the Ab1 pAD group, the Ab1 and Ab2 MCI and NC groups, and the cognitively normal APOE4 carrier and noncarrier groups but not in the Ab2 dementia group. In comparison, when the pontine reference ROI was used, there were small but significant SUVR increases only in the Ab1 NC group (P , 0.005) and the Ab1 MCI, Ab2 NC, and cognitively normal APOE4 carrier and noncarrier groups (0.005 , P , 0.05), and there was a failure to detect significant SUVR increases in the Ab1 and Ab2 dementia and Ab2 MCI groups. When the cerebellar reference ROI was used, there were small but significant SUVR increases only in the Ab2 NC group (P , 0.005) and the Ab1 and cognitively normal APOE4 carrier groups (0.005 , P , 0.05), and there was a failure to detect significant SUVR increases in any of the dementia or MCI groups. For each Ab1 or Ab2 subgroup in the pAD, MCI, and NC groups and for each cognitively normal APOE4 carrier or noncarrier subgroup, 24-mo cerebral-to-white matter SUVR increases were significantly greater than cerebral-to-pons SUVR increases (P , 0.05), except in the NC Ab1 group (P 5 0.065). The cerebral-to-white matter SUVR increases over 24 mo were also higher than the cerebral-to-cerebellar SUVR increases in the AD Ab1 and MCI Ab1 groups ( Table 3) .
As shown in Figure 2 for individual Ab1 and Ab2 pAD patients together, SUVRs generated with the cerebral white matter ROI appeared less variable and were less likely to show paradoxical decreases than those generated with the pontine and cerebellar ROIs. Ratings on ADAS-Cog13 were not available for 3 of these subjects. ‡ Scores on MMSE and ratings on ADAS-Cog13 were not available for 5 and 6 of these subjects, respectively.
The trend toward changes in cerebral-to-cerebral white matter SUVRs from the baseline to the follow-up at 24 mo seemed more consistent across individual patients (and therefore resulted in reduced variability) (Fig. 2) . Similar findings were observed in the other groups.
As shown in Table 4 , the estimated number of participants needed per arm to detect a 25% effect of treatment on further SUVR increases in a 12-mo placebo-controlled randomized clinical trial with 80% power and a 2-tailed P value of 0.05 was far smaller when the cerebral white matter reference ROI was used than when either the pontine or the cerebellar reference ROI was used, regardless of subject group. Because the power estimates were made for treatments that were not expected to actually clear existing fibrillar Ab, the number of participants needed was quite high; still, the number was dramatically smaller when the cerebral white matter reference ROI was used.
As also shown in Table 4 , the estimated number of participants needed to detect a 25% decrease in the SUVR from the baseline to 12 mo was much smaller than that needed to detect attenuation in further SUVR increases. Still, the number needed to detect this treatment effect was smaller when the cerebral white matter reference ROI was used than when either the pontine or the cerebellar reference ROI was used.
Correlations between 24-mo SUVR increases and clinical declines in the aggregate group of 31 pAD patients, 187 MCI patients, and 114 NCs with the different reference ROIs are shown in Table 5 . The cerebral white matter reference ROI permitted us to demonstrate significant correlations between 24-mo SUVR increases and 24-mo MMSE score decreases (R 5 20.22), ADAS-Cog13 rating increases (R 5 0.24), and CDR-SB score increases (R 5 0.22) (P , 0.001). Significant correlations in the predicted direction were not observed with either the pontine or the cerebellar reference ROI. (None was able to detect such significant correlations in the individual subject groups, probably because of limited sample sizes.)
DISCUSSION
The present study demonstrated the improved power of florbetapir SUVRs to track longitudinal fibrillar Ab increases, to characterize their relationship to longitudinal clinical declines, and to † P values reflect differences between respective Aβ1 vs. Aβ− or NC APOE4 carrier vs. noncarrier SUVR changes. ‡ For within-group SUVR increases, P value was .0.005 but #0.05. § For within-group SUVR increases, P value was #0.005. jj Data are reported as P values, which reflect SUVR change differences between use of cerebral white matter vs. pons or between use of cerebral white matter vs. cerebellum in each group.
evaluate Ab-modifying treatments with a cerebral white matter reference ROI instead of a cerebellar or pontine reference ROI. Our decision to test the ability of the cerebral white matter reference ROI to improve power in longitudinal studies was based on the possibility that some of the variability in sequential SUVRs is attributable to the combined effects of differences in betweenscan head positioning and the differential impact on measurements in a cerebral ROI (near the center of the field of view) and cerebellar and pontine ROIs (closer to the inferior field of view). We reasoned that measurements from a cerebral white matter reference ROI located approximately in the same plane as the cerebral ROI would be less vulnerable to such effects. We further reasoned that PET measurements from the cerebral white matter ROI would be less likely to be confounded by the combined effects of partial-volume averaging and spillover from cerebral gray matter because fibrillar Ab measurements are unlikely to change over a relatively limited time.
Although our findings support the use of a cerebral white matter reference ROI for the analysis of longitudinal florbetapir PET scans, additional studies are needed to clarify whether the observed improvements in longitudinal tracking are due to differences in head repositioning in PET scanners or to other factors that influence the reference ROI measure. We are now seeking radiation dose and patient body weight data from the ADNI and other studies to compute SUVs and to clarify the extent to which there is a preferential decline in our white matter ROI SUVs (e.g., because of progressive ventricular enlargement), the extent to which there is a preferential decline in gray matter SUVs (e.g., because of progressive gray matter atrophy), and the extent to which the variability in repeated SUVs differs among white matter, cerebellar, and pontine ROIs. We predict that our white matter ROI may lead to a slight overestimation of SUVR increases, particularly in AD patients, but that this possibility does not solely account for the improvements in the power to track SUVRs. Because Ab PET radioligands differ in their nonspecific white matter binding, it remains to be determined whether our findings can be generalized to other radioligands and to more quantitative measurements, such as the distribution volume ratio (23). Although we have not yet clarified whether longitudinal changes in white matter integrity or nonspecific binding could increase variability in cerebral-to-white-matter SUVRs, we were still able to detect improvements in precision between baseline and follow-up SUVRs. Finally, we do not believe that the improvements in SUVR variability were due to the size of the reference ROI and improved counting statistics, because the number of voxels (10,482) in our white matter ROI was smaller than that in the cerebellar ROI (13,583) and because we continued to see improved precision in a post hoc analysis of SUVRs with voxels from only the corpus callosum.
In the present study, we used a template-based cerebral white matter ROI consisting of voxels from the corpus callosum and the centrum semiovale. We have also found similar benefits of the cerebral white matter ROI and similar sample size estimates whether one evaluates changes in absolute SUVRs or the percentage change from baseline. Our data are available at the ADNI Web site. Additional studies are needed to compare our findings with those generated from individual MR imaging-based cerebral white matter ROIs. For now, we recommend using our white matter reference ROI for longitudinal analyses, and we have made the template publicly available on the ADNI website. We also recommend the use of a cerebellar or pontine reference ROI in cross-sectional comparisons (e.g., to determine Ab positivity or negativity).
Using a method with improved power to track longitudinal SUVR increases, we found a relationship between longitudinal SUVR increases and clinical declines in the aggregate group of pAD, MCI, and NC subjects-a possibly novel finding that may provide additional support for the amyloid hypothesis. As mentioned earlier, the use of cerebral white matter ROIs to measure SUVR increases could overestimate longitudinal SUVR increases because of the combined effects of brain atrophy-related ventricular enlargement and partial-volume averaging, such that measurements in the reference ROI are progressively reduced. Although we cannot exclude that possibility, the improved power to characterize longitudinal SUVR increases was similar in the pAD, MCI, and NC groups, despite likely differences in ventricular enlargement rates.
As previously stated, longitudinal florbetapir PET SUVRs were more variable than predicted with a cerebellar or pontine reference ROI, and some of this variability may have been related to technical rather than biologic reasons. Because the technical source of variability could affect the power to detect treatment effects in clinical trials, including some that have already been reported, we recommend a reanalysis of data with a cerebral white matter reference ROI to determine whether any of the Ab-modifying treatments now in development may have a greater effect than previously realized.
CONCLUSION
Our findings support the use of a cerebral white matter reference ROI to track longitudinal fibrillar Ab increases with semiquantitative florbetapir PET measurements, to relate those increases to longitudinal clinical declines, and to evaluate Ab-modifying effects with increased statistical power. 
